Biological Omics Analysis of Tumor Mutation Burden Combined with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma

Background: In various malignancies, whether tumor mutation burden (TMB) is associated with improved survival outcomes or enhanced immunotherapy remains controversial. We are committed to exploring the prognosis of TMB and its potential association with immune infiltration of uterine corpus endometrial cancer (UCEC).Methods: We downloaded transcriptome data and somatic mutation data from the Cancer Genome Atlas (TCGA) database, and visualized the mutation profiles using the "maftools" package. TMB was calculated and the samples were divided into two groups by the median. Kaplan-Meier analysis and Wilcoxon test were used to compare the differences in survival and clinicopathological characteristics. Furthermore, we performed functional enrichment analysis to screen for significant contributing pathways. The "CIBERSORT" package was used to estimate the abundance of immune components. Differential analysis was performed using the "limma" package to compare gene expression profiles. Multivariate analysis was used to identify risk genes related to TMB. Based on these genes, a risk model was established, and the receiver operating characteristic (ROC) curve was drawn to assess the predictive accuracy. Finally, we evaluated the relationship between risk genes and immune infiltration using the Timer database.Results: The mutation data included 542 UCEC patients. The waterfall plot summarized the specific mutation information. Higher TMB levels indicated improved overall survival (OS) (p =0.048) and were associated with advanced grades. Pathway analysis showed that the differential signals were enriched in multiple immune-related crosstalks. We screened 108 differentially expressed genes in two TMB groups and identified four risk-related genes. The model based on these four risk genes had good predictive value, the area under the curve (AUC) = 0.670, and patients with higher risk scores showed worse OS (p <0.001). Additionally, CD8 T cells memory-activated, CD4 T cells, and M1 macrophages in the high TMB group showed higher infiltrates, while regulatory T cells (Tregs) and M2 macrophages showed lower infiltrates.Conclusions: Higher TMB was associated with better survival outcomes and increased the immune infiltration in the tumor microenvironment of UCEC.

[1]  Jia Lv,et al.  Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer , 2020, Bioscience reports.

[2]  A. Green,et al.  A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[3]  E. Yakirevich,et al.  Tumor mutational burden and immune signatures interplay in renal cell carcinoma , 2020, Annals of translational medicine.

[4]  Michael S. Goldberg,et al.  Improving cancer immunotherapy through nanotechnology , 2019, Nature Reviews Cancer.

[5]  Jianliu Wang,et al.  The Role of Metabolic Syndrome in Endometrial Cancer: A Review , 2019, Front. Oncol..

[6]  A. Haque,et al.  Development of circulating CD4+ T‐cell memory , 2019, Immunology and cell biology.

[7]  S. Khakoo,et al.  Immunotherapy for hepatocellular carcinoma: Current and future , 2019, World journal of gastroenterology.

[8]  C. Marchetti,et al.  Immune check-point in endometrial cancer , 2019, International Journal of Clinical Oncology.

[9]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Puja Sharma,et al.  Receptor-Targeted Glial Brain Tumor Therapies , 2018, International journal of molecular sciences.

[11]  Yong Teng,et al.  Making way for suppressing the FGF19/FGFR4 axis in cancer. , 2018, Future medicinal chemistry.

[12]  B. Taylor,et al.  Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer , 2018, Clinical Cancer Research.

[13]  Guangxu Jin,et al.  Tumor mutational burden is a determinant of immune-mediated survival in breast cancer , 2018, Oncoimmunology.

[14]  Arun Ahuja,et al.  Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer , 2018, Cancer cell.

[15]  E. Jaffee,et al.  Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.

[16]  R. Puri,et al.  Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme , 2017, Journal of Neuro-Oncology.

[17]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[18]  K. Schmitz,et al.  Obesity and Endometrial Cancer: A Lack of Knowledge but Opportunity for Intervention , 2017, Nutrition and cancer.

[19]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[20]  Ping-Chih Ho,et al.  Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy. , 2017, Trends in cancer.

[21]  R. Madan,et al.  Immunotherapy of Prostate Cancer: Facts and Hopes , 2017, Clinical Cancer Research.

[22]  H. Rugo,et al.  Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Schadendorf,et al.  Immunotherapy in melanoma: Recent advances and future directions. , 2017, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  R. Herbst,et al.  Immunotherapy in Lung Cancer. , 2017, Hematology/oncology clinics of North America.

[25]  A. Oza,et al.  Treatment strategies for endometrial cancer: current practice and perspective , 2017, Current opinion in obstetrics & gynecology.

[26]  S. Devadas,et al.  Regulators of Tfh Cell Differentiation , 2016, Front. Immunol..

[27]  R. Motzer,et al.  Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma , 2016, Nature Reviews Urology.

[28]  E. Nowakowska-Zajdel,et al.  Epigenetic silencing of endothelin-3 in colorectal cancer , 2016, International journal of immunopathology and pharmacology.

[29]  Michael M. Braun,et al.  Diagnosis and Management of Endometrial Cancer. , 2016, American family physician.

[30]  Lauren L. Ritterhouse,et al.  Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.

[31]  M. Raes,et al.  M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide , 2015, BMC Cancer.

[32]  S. Kondo,et al.  Clinical Development of Immune Checkpoint Inhibitors , 2015, BioMed research international.

[33]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[34]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[35]  F. Amant,et al.  Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy , 2014, Cancer Immunology, Immunotherapy.

[36]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[37]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[38]  Hassan Ashktorab,et al.  Epigenetic inactivation of endothelin‐2 and endothelin‐3 in colon cancer , 2013, International journal of cancer.

[39]  J. Casal,et al.  High expression of IL-13 receptor α2 in colorectal cancer is associated with invasion, liver metastasis, and poor prognosis. , 2012, Cancer research.

[40]  H. Kitchener,et al.  Adjuvant radiotherapy for stage I endometrial cancer. , 2012, The Cochrane database of systematic reviews.

[41]  M. Jenkins,et al.  Origins of CD4+ effector and central memory T cells , 2011, Nature Immunology.

[42]  A. N. Meyer,et al.  The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling , 2010, PloS one.

[43]  M. Esteller,et al.  Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer , 2009, Breast Cancer Research.

[44]  Y. Liu,et al.  Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells. , 2007, Human pathology.

[45]  R W Raven,et al.  The british association of surgical oncology , 1973, Annals of the Royal College of Surgeons of England.

[46]  L. Liau,et al.  Cell-Based Immunotherapy of Gliomas. , 2018, Progress in neurological surgery.

[47]  M. Brewer,et al.  Endometrial Cancer: Is This a New Disease? , 2017, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[48]  I. Simera,et al.  Adjuvant radiotherapy for stage I endometrial cancer. , 2007, The Cochrane database of systematic reviews.

[49]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.